NASDAQ:FOLD
Amicus Therapeutics Stock News
$10.54
-0.170 (-1.59%)
At Close: Apr 24, 2024
Amicus (FOLD) Gets Pompe Disease Treatment Approval in Europe
12:15pm, Tuesday, 28'th Mar 2023
Amicus (FOLD) receives approval from the European Commission to treat the adult late-onset Pompe disease with Pombiliti (cipaglucosidase alfa).
Amicus Therapeutics (FOLD) Reports Q4 Loss, Tops Revenue Estimates
11:18am, Wednesday, 01'st Mar 2023
Amicus Therapeutics (FOLD) delivered earnings and revenue surprises of -46.15% and 1.44%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Amicus Therapeutics to Present at the Cowen 43rd Annual Health Care Conference
07:00am, Monday, 27'th Feb 2023
PHILADELPHIA, Feb. 27, 2023 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that management will participate in a fireside chat at the Cowen 43rd Annual Health Care Conference i
Amicus Therapeutics to Announce Full-Year 2022 Financial Results on March 1, 2023
07:00am, Tuesday, 14'th Feb 2023
PHILADELPHIA, Feb. 14, 2023 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that the Company will host a conference call and live audio webcast on Wednesday, March 1, 2023 at 8:
Amicus Therapeutics to Present at the SVB Securities Global Biopharma Conference
07:00am, Wednesday, 08'th Feb 2023
PHILADELPHIA, Feb. 08, 2023 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that management will participate in a fireside chat at the SVB Securities Global Biopharma Conference
Amicus: While AT-GAA For Pompe Faces Delay, Troubles Slowly Raise Their Heads
08:57am, Sunday, 15'th Jan 2023
AT-GAA's US approval is still held up by the China delay. Meanwhile, the company faces the risk of appearing overvalued.
Amicus Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference
07:00am, Tuesday, 03'rd Jan 2023
PHILADELPHIA, Jan. 03, 2023 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that Bradley Campbell, President and Chief Executive Officer, will present at the 41st Annual J.P. Mo
Amicus Therapeutics Receives Positive CHMP Opinion for Pombiliti™ (cipaglucosidase alfa) for Late-Onset Pompe Disease
01:10pm, Friday, 16'th Dec 2022 GlobeNewswire Inc.
CHMP Adopts Positive Opinion Based Upon Complete Review of all Pre-Clinical, Clinical Studies and CMC Data
Why Is Amicus Therapeutics (FOLD) Up 13.7% Since Last Earnings Report?
04:30pm, Wednesday, 07'th Dec 2022 Zacks Investment Research
Amicus Therapeutics (FOLD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Amicus releases phase 3 results in Pompe disease trial
09:14am, Saturday, 19'th Nov 2022
CNBC's senior health and science reporter Meg Tirrell reports Amicus showed results in its phase 3 trial to address Pompe disease. The drug showed it can help people walk and significantly slowed the
Amicus Therapeutics to Present at the Stifel 2022 Healthcare Conference
12:00pm, Tuesday, 15'th Nov 2022 GlobeNewswire Inc.
PHILADELPHIA, Nov. 15, 2022 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that management will participate in a fireside chat at the Stifel 2022 Healthcare Conference in New
Amicus Therapeutics to Present at the Stifel 2022 Healthcare Conference
07:00am, Tuesday, 15'th Nov 2022
PHILADELPHIA, Nov. 15, 2022 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that management will participate in a fireside chat at the Stifel 2022 Healthcare Conference in New Y
Amicus (FOLD) Q3 Earnings Beat, Galafold Sales Miss Estimates
04:15pm, Tuesday, 08'th Nov 2022 Zacks Investment Research
Amicus Therapeutics (FOLD) posts a narrower-than-expected loss in the third quarter. FOLD's sole marketed drug Galafold's solid sales drive the top line.
Amicus (FOLD) Q3 Earnings Beat, Galafold Sales Miss Estimates
12:47pm, Tuesday, 08'th Nov 2022
Amicus Therapeutics (FOLD) posts a narrower-than-expected loss in the third quarter. FOLD's sole marketed drug Galafold's solid sales drive the top line.
Amicus Therapeutics Provides EU Regulatory Update for AT-GAA
05:20pm, Monday, 07'th Nov 2022 GlobeNewswire Inc.
PHILADELPHIA, Nov. 07, 2022 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD), a patient-dedicated global biotechnology company focused on developing and commercializing novel medicines for rar
